Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Efficacy and safety of temsirolimus in Japanese patients with metastatic renal cell carcinoma on hemodialysis

Efficacy and safety of temsirolimus in Japanese patients with metastatic renal cell carcinoma on... Int J Clin Oncol (2013) 18:1054–1059 DOI 10.1007/s10147-012-0492-7 O R I G IN AL ARTI CL E Efficacy and safety of temsirolimus in Japanese patients with metastatic renal cell carcinoma on hemodialysis • • Hideaki Miyake Ken-ichi Harada Yuji Kusuda Masato Fujisawa Received: 25 August 2012 / Accepted: 14 October 2012 / Published online: 1 November 2012 Japan Society of Clinical Oncology 2012 Abstract C grade 3 occurred in only four, including thrombocyto- Background We retrospectively investigated the efficacy penia in two, anemia in one, and asthenia in one. and safety of temsirolimus, an inhibitor of the mammalian Conclusions Treatment with temsirolimus is well toler- target of rapamycin, in patients with metastatic renal cell ated and could provide comparatively favorable cancer carcinoma (mRCC) on hemodialysis (HD). control in Japanese mRCC patients undergoing HD. Methods This study included ten HD patients who were diagnosed with mRCC following radical nephrectomy and Keywords Renal cell carcinoma  Temsirolimus subsequently treated with temsirolimus between December Hemodialysis 2010 and June 2012. Medical records of these patients were reviewed to evaluate the response to temsirolimus and treatment-related toxicities. Introduction Results Baseline characteristics of the patients are as follows: median age was 61 years, five patients http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png International Journal of Clinical Oncology Springer Journals

Efficacy and safety of temsirolimus in Japanese patients with metastatic renal cell carcinoma on hemodialysis

Loading next page...
 
/lp/springer-journals/efficacy-and-safety-of-temsirolimus-in-japanese-patients-with-QOSk1qtC0M

References (26)

Publisher
Springer Journals
Copyright
Copyright © 2012 by Japan Society of Clinical Oncology
Subject
Medicine & Public Health; Oncology; Surgical Oncology; Cancer Research
ISSN
1341-9625
eISSN
1437-7772
DOI
10.1007/s10147-012-0492-7
pmid
23114786
Publisher site
See Article on Publisher Site

Abstract

Int J Clin Oncol (2013) 18:1054–1059 DOI 10.1007/s10147-012-0492-7 O R I G IN AL ARTI CL E Efficacy and safety of temsirolimus in Japanese patients with metastatic renal cell carcinoma on hemodialysis • • Hideaki Miyake Ken-ichi Harada Yuji Kusuda Masato Fujisawa Received: 25 August 2012 / Accepted: 14 October 2012 / Published online: 1 November 2012 Japan Society of Clinical Oncology 2012 Abstract C grade 3 occurred in only four, including thrombocyto- Background We retrospectively investigated the efficacy penia in two, anemia in one, and asthenia in one. and safety of temsirolimus, an inhibitor of the mammalian Conclusions Treatment with temsirolimus is well toler- target of rapamycin, in patients with metastatic renal cell ated and could provide comparatively favorable cancer carcinoma (mRCC) on hemodialysis (HD). control in Japanese mRCC patients undergoing HD. Methods This study included ten HD patients who were diagnosed with mRCC following radical nephrectomy and Keywords Renal cell carcinoma  Temsirolimus subsequently treated with temsirolimus between December Hemodialysis 2010 and June 2012. Medical records of these patients were reviewed to evaluate the response to temsirolimus and treatment-related toxicities. Introduction Results Baseline characteristics of the patients are as follows: median age was 61 years, five patients

Journal

International Journal of Clinical OncologySpringer Journals

Published: Nov 1, 2012

There are no references for this article.